Kidney Cancer (Renal Cell Cancer) (Oncology) - Drugs in Development, 2021
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) – Drugs In Development, 2021, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape.
Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 1, 24, 206, 212, 5, 16, 127, 26 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 15, 11, 2, 1, 16 and 1 molecules, respectively.
Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Kidney Cancer (Renal Cell Cancer) - Overview
Kidney Cancer (Renal Cell Cancer) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development
Kidney Cancer (Renal Cell Cancer) - Drug Profiles
Kidney Cancer (Renal Cell Cancer) - Dormant Projects
Kidney Cancer (Renal Cell Cancer) - Discontinued Products
Kidney Cancer (Renal Cell Cancer) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
List of Tables
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, 2021
Kidney Cancer (Renal Cell Cancer) - Discontinued Products, 2021
List of Figures
List of Figures
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021
3D Medicines Inc
4D Pharma Plc
4SC AG
Aadi Bioscience Inc
Abbisko Therapeutics Co Ltd
AbbVie Inc
ABL Bio Inc
Achilles Therapeutics UK Ltd
Acrotech Biopharma LLC
Actuate Therapeutics Inc
Adagene Suzhou Ltd
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Advenchen Laboratories LLC
Affimed GmbH
Affitech A/S
Agenus Inc
AIM ImmunoTech Inc
Akeso Inc
Alkermes Plc
Allarity Therapeutics A/S
Alligator Bioscience AB
Almac Discovery Ltd
Alpha-1 Biologics Corp
AlphaMab Co Ltd
Alphamab Oncology
Altor Bioscience LLC
ALX Oncology Holdings Inc
Ambrx Biopharma Inc
Amgen Inc
Amphivena Therapeutics Inc
Anaveon AG
Anhui Anke Biotechnology (Group) Co Ltd
AntiCancer Inc
Apcure SAS
Apexigen Inc
Apollomics Inc
Aprea Therapeutics Inc
Aprilbio Co Ltd
Aravive Inc
Arcus Biosciences Inc
Argenx SE
Arrowhead Pharmaceuticals Inc
Ascentage Pharma Group International
Ashvattha Therapeutics LLC
Astellas Pharma Inc
AstraZeneca Plc
Atreca Inc
Aurigene Discovery Technologies Ltd
Avesthagen Ltd
Bacchus Therapeutics Inc
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Beijing Eastern Biotech Co Ltd
Beijing Foreland Pharma Co Ltd
Beijing Kawin Technology Share-Holding Co Ltd
Beijing Konruns Pharmaceutical Co Ltd
Beijing Scitech-MQ Pharmaceuticals Ltd
Benhealth Biopharmaceutical (Shenzhen) Co Ltd
BerGenBio ASA
BeyondSpring Inc
Bicycle Therapeutics Plc
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
BioAtla Inc
Biocad
Biocon Ltd
Biohaven Pharmaceutical Holding Company Ltd
BioIntegrator Ltd
Biomica
Bionomics Ltd
BioNTech SE
Biosion Inc
Biotheus Inc
BioVaxys Technology Corp
BioXpress Therapeutics SA
Boehringer Ingelheim International GmbH
BridgeBio Pharma Inc
Bristol-Myers Squibb Co
Byondis BV
Calico Life Sciences LLC
Calithera Biosciences Inc
CanBas Co Ltd
Canget BioTekpharma LLC
Cantargia AB
Catamaran Bio Inc
Cbiomex Co Ltd
Celdara Medical LLC
Celldex Therapeutics Inc
Celyad Oncology SA
Centurion BioPharma Corp
CG Oncology Inc
Checkpoint Therapeutics Inc
CicloMed LLC
Clovis Oncology Inc
COARE Biotechnology Inc
Coherent Biopharma
CoImmune Inc
Constellation Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
Cothera Bioscience Pty Ltd
CRISPR Therapeutics AG
CSPC Pharmaceutical Group Ltd
CureLab Oncology Inc
Curigin Co Ltd
Curis Inc
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Deciphera Pharmaceuticals Inc
Deka Biosciences Inc
DevaCell Inc
DNAtrix Inc
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Dragonfly Therapeutics Inc
Duet Therapeutics Inc
Dyadic International Inc
Ecrins Therapeutics SAS
Eddingpharm Inc
eFFECTOR Therapeutics Inc
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
Ella Therapeutics Ltd
Ellipses Pharma Ltd
Enara Bio Ltd
Enochian Biosciences Inc
EpimAb Biotherapeutics Inc
Epizyme Inc
Epygen Biotech Pvt Ltd
Esanex Inc
Esperance Pharmaceuticals Inc
eTheRNA Immunotherapies NV
Evaxion Biotech ApS
Exelixis Inc
EXUMA Biotech Inc
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Fate Therapeutics Inc
G1 Therapeutics Inc
GEMoaB Monoclonals GmbH
Genentech USA Inc
Geneos Therapeutics Inc
Generium
GenFleet Therapeutics (Shanghai) Inc
Genmab AS
Genocea Biosciences Inc
Genome & Co
Gilead Sciences Inc
GlaxoSmithKline Plc
GLG Pharma SA
Glycotope GmbH
GlyTherix Ltd
GT Biopharma Inc
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Hanghua Bio Pharmaceutical Technology Co
Hainan Kaibo Biotechnology Co Ltd
Handa Pharmaceuticals LLC
Hangzhou Zenshine Pharmaceuticals Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
Helixmith Co Ltd
Hengenix Biotech Inc
Hibercell Inc
HitGen Inc
Horizon Therapeutics Plc
Hualan Biological Engineering Inc
Hutchison MediPharma Ltd
I-Mab
Idera Pharmaceuticals Inc
Ikena Oncology Inc
Immune Pharmaceuticals Inc
Immune Therapeutics Inc
ImmuneCyte Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneSensor Therapeutics Inc
Immunicum AB
ImmunityBio Inc
Immunocore Holdings Plc
ImmunoGen Inc
Imugene Ltd
Incyte Corp
Infinity Pharmaceuticals Inc
Inhibrx Inc
Inmune Bio Inc
InnoCare Pharma Ltd
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
InSight Biopharmaceuticals Ltd (Inactive)
InteRNA Technologies BV
Invectys SA
IO Biotech Inc
Istari Oncology Inc
Iterion Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Jounce Therapeutics Inc
JSK Therapeutics Inc
Jubilant Therapeutics Inc
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kidswell Bio Corp
Kind Pharmaceuticals
Kinnate Biopharma Inc
Kintor Pharmaceutical Ltd
KLUS Pharma Inc
Komipharm International Co Ltd
Kuda Therapeutics Inc
Kymab Ltd
Kyowa Kirin Co Ltd
LaNova Medicines Ltd
Lantern Pharma Inc
Lead Discovery Center GmbH
Lindis Biotech GmbH
Lipac Oncology LLC
Lotus Pharmaceutical Co Ltd
Loxo Oncology Inc
Luye Pharma Group Ltd
Lycera Corp
Lytix Biopharma AS
Mabwell Shanghai Bioscience Co Ltd
MacroGenics Inc
Mana Therapeutics Inc
Mantis Therapeutics BV
Marino Biotechnology Co Ltd
MaxiVAX SA
MdBioLab
Medicenna Therapeutics Corp
MediciNova Inc
MedPacto Inc
Merck & Co Inc
Merck KGaA
Metagone Biotech Inc
Metis Precision Medicine
Microbiotica Ltd
MicuRx Pharmaceuticals Inc
Midissia Therapeutics Inc
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Miyarisan Pharmaceutical Company Ltd
Moderna Inc
Modulation Therapeutics Inc
Molecular Partners AG
Molecular Templates Inc
Moleculin Biotech Inc
Multitude therapeutics Inc
MultiVir Inc
Mycenax Biotech Inc
Nanjing Aimeifei Biomedical Technology Co Ltd
NanoCarrier Co Ltd
Nanology LLC
Nektar Therapeutics
Neoleukin Therapeutics Inc
NeoTX Therapeutics Ltd
NeuClone Pty Ltd
New Beta Innovation Ltd
NGM Biopharmaceuticals Inc
NiKang Therapeutics Inc
Novartis AG
Nurix Therapeutics Inc
Ocellaris Pharma Inc
Ocuphire Pharma Inc
Omeros Corp
OncoC4 Inc
Oncolys BioPharma Inc
Onconova Therapeutics Inc
OncoQuest Inc
Oncorena AB
Oncorus Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Orion Corp
Orpheus Therapeutics Inc
Pact Pharma Inc
Pathios Therapeutics Ltd
Pfizer Inc
Pharma Mar SA
PharmAbcine Inc
PharmaTher Holdings Ltd
Pharmicell Co Ltd
Philogen SpA
Phosplatin Therapeutics LLC
Pinotbio Inc
Pionyr Immunotherapeutics Inc
PlantForm Corp
Prestige BioPharma Ltd
PsiOxus Therapeutics Ltd
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Qu Biologics Inc
Quadriga BioSciences Inc
Qualigen Therapeutics Inc
Race Oncology Ltd
RAPT Therapeutics Inc
Recombio SL
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Repertoire Immune Medicines Inc
Replimune Ltd
RevImmune SAS
Richter Gedeon Nyrt
Rizen (Suzhou) Biosciences Co Ltd
Ryvu Therapeutics SA
SA Science Inc
Samyang Biopharmaceuticals Corp
Sanofi
Sapphire Biotech Inc
Sareum Holdings Plc
Scancell Holdings Plc
Scholar Rock Inc
Schrodinger Inc
Seagen Inc
SELLAS Life Sciences Group Inc
Seneca Therapeutics Inc
Serum Institute of India Pvt Ltd
Seven and Eight Biopharmaceuticals Corp
Shandong New Time Pharmaceutical Co Ltd
Shandong Taize Huikang Biomedical Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Shanghai Escugen Biotechnology Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Bioscience Co Ltd
Shanghai Miracogen Inc
Shanghai Pharmaceutical Group Co Ltd
Shattuck Labs Inc
Shenzhen Chipscreen Biosciences Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
Shionogi & Co Ltd
Sichuan Huiyang Life Science and Technology Corp
Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Sinovation Bio-technology Co Ltd
SignalRx Pharmaceuticals Inc
Sillajen Biotherapeutics
Silverback Therapeutics Inc
Simcha Therapeutics Inc
Sonnet BioTherapeutics Holdings Inc
Sonoval LLC
Sorrento Therapeutics Inc
Sotio AS
ST Pharm Co Ltd
STADA Pharmaceuticals (Asia) Ltd
Statera BioPharma Inc
Steba Biotech SA
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Dainippon Pharma Oncology, Inc
Suntec Medical (Taiwan) Inc
Surface Oncology Inc
Suzhou Dingfu Target Biotechnology Co Ltd
Suzhou Stainwei Biotech Inc
Syndivia SAS
Synermore Biologics Co Ltd
SynOx Therapeutics Ltd
Systimmune Inc
T-Cure Bioscience Inc
Tactical Therapeutics Inc
TAE Life Sciences LLC
Taiho Oncology Inc
Taiho Pharmaceutical Co Ltd
Tarus Therapeutics Inc
TCR2 Therapeutics Inc
Telix Pharmaceuticals Ltd
Tempest Therapeutics Inc
Teon Therapeutics Inc
Theralink Technologies Inc
Toray Industries Inc
TotalClarity Inc
Treadwell Therapeutics Inc
Turning Point Therapeutics Inc
TVAX Biomedical Inc
Tyme Inc
UbiVac LLC
UCB SA
Unicyte AG
VasGene Therapeutics Inc
Vault Pharma Inc
Vaxiion Therapeutics Inc
Versameb AG
Viatris Inc
Vincerx Pharma Inc
Vyriad Inc
Western Oncolytics Ltd
WindMIL Therapeutics Inc
X4 Pharmaceuticals Inc
Xbrane Biopharma AB
Xcovery Holding Co LLC
Xencor Inc
Xilio Therapeutics Inc
Xynomic Pharmaceuticals Holdings Inc
Y-Biologics Inc
Y-mAbs Therapeutics Inc
Yantai Rongchang Pharmaceutical Co Ltd
Yuhan Corp
Zelluna Immunotherapy AS
Zymergen Inc
*If Applicable.